MODERNA INC (MRNA)
US60770K1079 - Common Stock
Overall MRNA gets a fundamental rating of 3 out of 10. We evaluated MRNA against 565 industry peers in the Biotechnology industry. MRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MRNA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MRNA has reported negative net income.
In the past year MRNA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: MRNA reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: MRNA reported negative operating cash flow in multiple years.
1.2 Ratios
MRNA has a Return On Assets of -14.07%. This is amongst the best in the industry. MRNA outperforms 84.67% of its industry peers.
Looking at the Return On Equity, with a value of -18.65%, MRNA belongs to the top of the industry, outperforming 86.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.07% | ||
| ROE | -18.65% | ||
| ROIC | N/A |
ROA(3y)18.74%
ROA(5y)2.74%
ROE(3y)31.99%
ROE(5y)4.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 78.43%, MRNA belongs to the best of the industry, outperforming 86.10% of the companies in the same industry.
In the last couple of years the Gross Margin of MRNA has declined.
MRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.43% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.72%
GM growth 5YN/A
2. Health
2.1 Basic Checks
MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRNA has been reduced compared to 1 year ago.
MRNA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MRNA has an improved debt to assets ratio.
2.2 Solvency
MRNA has an Altman-Z score of 3.63. This indicates that MRNA is financially healthy and has little risk of bankruptcy at the moment.
MRNA has a better Altman-Z score (3.63) than 77.54% of its industry peers.
MRNA has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
MRNA has a Debt to Equity ratio of 0.05. This is in the lower half of the industry: MRNA underperforms 62.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.63 |
ROIC/WACCN/A
WACC10.34%
2.3 Liquidity
MRNA has a Current Ratio of 4.39. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.39, MRNA is in line with its industry, outperforming 49.02% of the companies in the same industry.
MRNA has a Quick Ratio of 4.20. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
MRNA has a Quick ratio (4.20) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.39 | ||
| Quick Ratio | 4.2 |
3. Growth
3.1 Past
MRNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.75%, which is quite impressive.
The Revenue for MRNA has decreased by -44.29% in the past year. This is quite bad
Measured over the past years, MRNA shows a very strong growth in Revenue. The Revenue has been growing by 119.30% on average per year.
EPS 1Y (TTM)37.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.31%
Revenue 1Y (TTM)-44.29%
Revenue growth 3Y104.31%
Revenue growth 5Y119.3%
Sales Q2Q%1.69%
3.2 Future
The Earnings Per Share is expected to grow by 24.00% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 15.24% on average over the next years. This is quite good.
EPS Next Y22.62%
EPS Next 2Y13.43%
EPS Next 3Y14.08%
EPS Next 5Y24%
Revenue Next Year-50.04%
Revenue Next 2Y-30.94%
Revenue Next 3Y-14.56%
Revenue Next 5Y15.24%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MRNA. In the last year negative earnings were reported.
Also next year MRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MRNA's earnings are expected to grow with 14.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.43%
EPS Next 3Y14.08%
5. Dividend
5.1 Amount
No dividends for MRNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MODERNA INC
NASDAQ:MRNA (11/21/2024, 3:40:08 PM)
38.285
+1.34 (+3.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap14.73B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.07% | ||
| ROE | -18.65% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.43% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.39 | ||
| Quick Ratio | 4.2 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)37.75%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y22.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-44.29%
Revenue growth 3Y104.31%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y